November 11, 2026 · Lancet (London, England) · DOI: 10.1016/S0140-6736(26)01953-7

Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.

Listen to this summary

The COURAGE trial asked whether blocking myostatin (GDF8) with trevogrumab, alone or combined with activin A blockade via garetosmab, could preserve lean mass during semaglutide-induced weight loss in adults with obesity. Trevogrumab significantly preserved lean mass relative to semaglutide plus placebo (about +1.5% to +3.1% treatment differences, depending on dose and part), and trevogrumab was generally well tolerated, whereas the trevogrumab 400 mg plus garetosmab combination produced more fat loss and weight loss but had a high rate of serious adverse events, treatment discontinuations, and two deaths (not causally linked to treatment), with more frequent muscle spasms.

Ofri Mosenzon, Julio Rosenstock, José G Raya, Joseph S Grimsby, Roberto A Calle, Kevin Cannon, Amina Z Haggag, Harold Bays, Neena Sarkar, Alison Templeton, Michelle Fanous, Jennifer Lighter, Andrea Vavere, George D Yancopoulos, Boaz Hirshberg

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play